Biomedcode’s preclinical models: Priming drugs for success but also … predicting drug failure!A new clinical study published by GlaxoSmithKline confirms findings in Biomedcode's TNF-DARE models.
30 SEP 2015
Select the type of mice you are interested in.
Therapeutic Areas - Animal models
12 APR 2016
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on Samsung Bioepis' Flixabi®a biosimilar version of Remicade (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis,...
FAQ - Top 10 Questions
As with everything the best thing is to book your study in advance. The earlier you contact us, the easier will be to choose the exact date for the...
Events and Webinars
Biomedcode was founded in 2006, as a spin-off of the Biomedical Sciences Research Center “Alexander Fleming”
Biomedcode has extensive expertise & scientific excellence in inflammatory & autoimmune animal disease models
Our mouse models of arthritis were instrumental in proving the efficacy of anti-hTNF therapeutics in arthritis
Biomedcode’s clients include top 5 worldwide pharmaceutical companies
Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In...Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, Davies ML, Stoop AA. PLoS One. 2015 Sep 9;10(9)
Animal models as a tool to dissect pivotal pathways driving spondyloarthritisVieira-Sousa E, van Duivenvoorde LM, Fonseca JE, Lories RJ, Baeten DL. Arthritis Rheumatol. 2015 Jul 20. doi: 10.1002/art.39282. [Epub ahead of...
Regulation of tumour necrosis factor signalling: live or let dieBrenner D, Blaser H, Mak TW, 2015, Nat. Rev. Immunol., May 26;15(6):362-74. doi: 10.1038/nri3834. Abstract: Tumour necrosis factor (TNF) is a...